Maze Therapeutics, Inc. (MAZE) stock
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.20−1.67 (-5.08%)
Close on Nov 18, 2026Market cap $1.73BP/E –Yield –
Maze Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Maze Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$145.61M. For fiscal 2025 it was -$142.90M, down 348.1% from the year before.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$142.90M | -348.1% |
| FY2024 | Dec 31, 2024 | $57.59M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$48.04M | – |
| Q1 FY2026 | Mar 31, 2026 | -$26.55M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.97M | – |
| Q2 FY2025 | Jun 30, 2025 | -$36.47M | -126.1% |
| Q1 FY2025 | Mar 31, 2025 | -$35.40M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.23M | – |
| Q2 FY2024 | Jun 30, 2024 | $139.56M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.01M | – |
See a number that looks wrong?